Clinical Trial Update: Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial

View source ↗

Summary

This clinical trial update describes the use of circulating tumor DNA genotyping to biologically monitor patients in the FIL-Rouge trial for Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Hodgkin Lymphoma | Status: COMPLETED